Does the timing of mTOR inhibition have to match the body's own pulses — feeding, exercise, sleep?

Framing gap · evidence stands at: Lifespan in mice · Atlas ID F4

The gap

Giving the drug once a week instead of daily is usually explained as a way to lower the dose and avoid side effects. But if the pathway cares about rhythm, the question is not how often you give it — it is whether the gaps in the drug line up with the moments the body actually needs the pathway on, like after a meal or after exercise. Nobody has tested that alignment.

Technical framing: Intermittent dosing is currently justified as a way to lower exposure and dodge side effects. But if the pathway reads pattern rather than level, the interesting variable is not how often the drug is given but whether the drug's troughs line up with the body's own peaks — the post-meal window, the post-exercise anabolic window, the circadian trough. No lifespan study has ever varied the phase of dosing while holding the dose and the interval constant.

What changed

The one head-to-head schedule comparison in exercising mice found that weekly and thrice-weekly rapamycin both preserved hypertrophy and grip strength, and that the schedule mattered for glucose rather than for muscle (Elliehausen, Aging Cell 2025, PMID 40704394). That is evidence that schedule does something — and evidence that the field's stated reason for choosing a schedule was the wrong one. Intermittent dosing has also now shown lifespan extension in its own right, in female C57BL/6J mice (Arriola Apelo, J Gerontol A 2016, PMID 27091134).

What is still open

Phase, as distinct from frequency. Does the same weekly dose given before against after the feeding window, or before against after exercise, produce different lifespan, muscle and glucose outcomes? This is a cheap experiment by ageing-research standards and it has not been run.

How it could be tested

A lifespan cohort at one dose and one interval, with dosing phase as the only variable — aligned with the light-phase trough, aligned with the feeding window, aligned post-exercise. Endpoints: lifespan, grip strength and contractile force, glucose tolerance, and mTORC1 and mTORC2 substrate phosphorylation sampled at several times of day rather than once.

Why it matters

It is the practical form of F1 and it is testable now with existing drugs. If phase matters, every current human trial has been dosing blind to a variable that decides the answer.

Bears on these open questions

• Muscle-sparing, pulsed mTORC1 inhibition
• mTORC1-selective (mTORC2-sparing) dosing captures longevity without insulin resistance
• Low-dose mTOR inhibition rejuvenates the aging immune system without net immunosuppression

← All frontier questions · Open questions